KNE Stock Overview
A biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Kane Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.14 |
| 52 Week High | CA$0.17 |
| 52 Week Low | CA$0.05 |
| Beta | 0.55 |
| 11 Month Change | -3.45% |
| 3 Month Change | 12.00% |
| 1 Year Change | 64.71% |
| 33 Year Change | -20.00% |
| 5 Year Change | 12.00% |
| Change since IPO | -92.00% |
Recent News & Updates
Shareholder Returns
| KNE | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | -0.3% |
| 1Y | 64.7% | -40.0% | 10.9% |
Return vs Industry: KNE exceeded the Canadian Biotechs industry which returned -40% over the past year.
Return vs Market: KNE exceeded the Canadian Market which returned 10.1% over the past year.
Price Volatility
| KNE volatility | |
|---|---|
| KNE Average Weekly Movement | 12.3% |
| Biotechs Industry Average Movement | 12.4% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in CA Market | 16.7% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: KNE has not had significant price volatility in the past 3 months.
Volatility Over Time: KNE's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Marc Edwards | kanebiotech.com |
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Kane Biotech Inc. Fundamentals Summary
| KNE fundamental statistics | |
|---|---|
| Market cap | CA$17.89m |
| Earnings (TTM) | -CA$4.94m |
| Revenue (TTM) | CA$165.60k |
112.0x
P/S Ratio-3.8x
P/E RatioIs KNE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KNE income statement (TTM) | |
|---|---|
| Revenue | CA$165.60k |
| Cost of Revenue | CA$44.23k |
| Gross Profit | CA$121.37k |
| Other Expenses | CA$5.06m |
| Earnings | -CA$4.94m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.037 |
| Gross Margin | 73.29% |
| Net Profit Margin | -2,984.49% |
| Debt/Equity Ratio | -86.5% |
How did KNE perform over the long term?
See historical performance and comparison